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The influenza virus neuraminidase (NA) is essential for the virus life cycle. The rise of resistance mutations
against current antiviral therapies has increased the need for the development of novel inhibitors. Recent
efforts have targeted a cavity adjacent to the catalytic site (the 150-cavity) in addition to the primary catalytic
subsite in order to increase specificity and reduce the likelihood of resistance. This study details structural
and in vitro analyses of a class of inhibitors that bind uniquely in both subsites. Crystal structures of three
inhibitors show occupation of the 150-cavity in two distinct and novel binding modes. We believe these are
the first nanomolar inhibitors of NA to be characterized in this way. Furthermore, we show that one
inhibitor, binding within the catalytic site, offers reduced susceptibility to known resistance mutations via
increased flexibility of a pendant pentyloxy group and the ability to pivot about a strong hydrogen-bonding
network.
I
nfluenza viruses constitute a continuing threat to public health worldwide1. In addition to recurring seasonal
epidemics, the occasional appearance of pandemic strains serves as a reminder of the importance of plans for
influenza prevention and control. Beyond the annual production of vaccines, these plans have included the
stockpiling of antiviral drugs, most commonly the neuraminidase inhibitors Oseltamivir (1), Zanamivir (2) and,
more recently, Peramivir (3) (Fig. 1). The emergence of resistant strains to these drugs makes the development of
novel antivirals an urgent concern.
The Influenza neuraminidase (NA) surface glycoprotein is responsible for the cleavage of sialic acid residues
from the surface of the infected cell2. Inhibition of this process prevents the release of nascent virions from the
surface of the cell, reducing the spread of the infection. There are ten known subtypes of NA (N1-10)3, which have
been classified by phylogenetic analyses into two distinct groups: group 1 (N1, N4, N5, and N8) and group 2 (N2,
N3, N6, N7, and N9)4. The N10 subtype is considered to be a ‘‘NA-like’’ protein rather than a true NA as it was
found to have only 20–27% sequence identity with other NA subtypes. In addition, recombinant N10 protein
showed no or extremely low sialidase activity in assay using 29-(4-methylumbelliferyl)-a-D-N-acetylneuraminic
acid (4-MU-NANA) as a substrate or with natural substrates in a glycan microarray assay5,6. Early structures of
the catalytic head domain from group 2 subtypes N9 and N2 were the basis of drug development programmes
leading to the production of Oseltamivir and Zanamivir. However, more recently the elucidation of several
structures of group 1 NAs has highlighted key group-specific differences in the shape of the NA active site4.
Specifically, in the active sites of group 1 NAs a loop, consisting of residues 147–152 (the 150-loop), adopts a
conformation leading to the opening of a pocket to the side of the active site (also known as the 150 cavity).While
this cavity was present in structures of the apo form of most group-1 NAs (some controversy surrounds the
structure of the NA from aH1N1 2009 pandemic strain7–10), it appears to be closed by movement of the 150-loop
in response to ligand binding4. In the subsequent complex the 150-loop occupies a position similar to that
observed in structures of group-2 NAs.
The discovery of the 150-cavity has lead to the development of several inhibitors designed to exploit contacts in
this region and increase specificity11–14. In particular, p-tolyl-Neu5Ac2en (Fig. 1), an inhibitor based on the
transition state analogue Neu5Ac2en, was demonstrated to insert into the 150-cavity and prevent closure of
the 150-loop12. As a consequence, inhibition of NA activity by this compound was described as group-specific,
with substantially greater inhibition of group-1 than group-2 NAs. However, recently several studies have
indicated that movement of the 150-loop may not be restricted to group-1 NA. More specifically, molecular
dynamics studies have indicated that all NAs may retain the propensity for both ‘‘open’’ and ‘‘closed’’ states,
maintaining an equilibrium that varies between strains8,15,16. These in silico studies have been supported by
evidence of a partially open 150-loop in a complex of N2 and Oseltamivir17.
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In previous studies, we have described the synthesis and biological
characterization of a novel class of NA inhibitors related to
Oseltamivir13,18, 4–8 (Fig. 1). In these studies, this class was demon-
strated to inhibit NA activity at nanomolar concentrations in a
highly selective manner, with compound 7 showing the propensity
for significant group-specificity. Furthermore these compounds did
not inhibit the activity of mammalian neuraminidases, NEU3 and
NEU419, an off-target effect that has been observed with Zanamivir20.
The parental compound within this class is the Oseltamivir isomer 4,
in which the cyclohexene double bond has been moved to the C2–C3
position. Further extensions to this scaffold were employed at the C4
position, using either guanidino (5) or triazole (6–8) groups, the
latter of which were expected to project into the 150-cavity. Here
we report further biological characterization of 4 and 5, indicating
the guanidine derivative 5 offers reduced susceptibility to the known
Oseltamivir-resistance mutation H274Y. Furthermore we reveal
structures of 4–8 in complex with a group-1 NA. While complexes
of N8:4 and N8:5 interact in a manner similar to previous NA
inhibitors, the structures of N8:6–8 indicate novel binding modes
employing contacts with residues within the 150-loop and cavity.
These structures, in combination with our recently published mole-
cular dynamics studies using the same compounds15, suggest that the
movements within this region may be more complicated than prev-
iously thought.
Results
Inhibition of Oseltamivir-resistant viruses by compounds 4 and 5.
To investigate the efficiency of the novel NA antagonists 4 and 5
against Oseltamivir resistant strains, both compounds were tested in
an in vitro replication inhibition assay using A/Brisbane/59/2007
(Oseltamivir-sensitive,WT) and A/Brisbane/59/2007-like Oseltamivir-
resistant (H274Y) strains. Compounds 4 and 5 inhibited the replica-
tion of WT with ED50 values similar to, or lower than that achieved by
Oseltamivir (1) (Table 1, Supplementary Fig. S3). In contrast to 1 and
4, compound 5 showed inhibition of the resistant strain.
Structures of N8 in complex with Oseltamivir-related compounds 4
and 5. To understand the molecular basis behind the inhibitory
activity of this novel class of inhibitors, crystal structures of the
parental compounds 4 and 5 were obtained in complex with a
group-1 NA by soaking crystals of N8 [A/duck/Ukraine/1/63
(H3N8)] enzyme in 1 mM solutions of compound (Fig. 2). In both
N8:4 and N8:5 complexes, the inhibitors bound in a position and
orientation very similar to that observed previously in structures of
Figure 1 | Chemical structures of anti-influenza drugs and novel inhibitors. Structures of previously characterised compounds (a) and novel inhibitors
characterised in this study (b). Ki values were measured with virus-like particles containing N1 subtype neuraminidase
13.
www.nature.com/scientificreports
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N8:1 (Fig. 2a and b). In particular, N8:4 overlays almost exactly with
N8:1, with only a subtle repositioning of the C7 atom due to the
change in position of the double bond in the cyclohexene ring
relative to 1. Surprisingly, given the lower activity of compound 4 in
in vitro inhibition assays13, no further significant differences in the
position of the compound’s pendant groups or active site residues
were observed. The position of 5 in the N8 active site is similarly
conserved, with the addition of a guanidino group extending
towards the base of the active site in a position reminiscent of the
guanidino group of Zanamivir (N8:2) (Fig. 2c), but distinct from that
of Peramivir (N8:3) (Fig. 2d). The additional contacts made between
this group and the active site (specifically E227 and the backbone
carbonyls of W178 and D151) explains the increase in inhibitory
activity compared to 4.
Structures of N8 in complex with compounds (6–8) extending into
the 150 cavity. In addition to compounds 4 and 5, we also examined
the binding mode of three further members of this class of inhibitor,
6, 7, and 8, in complex with N8 by X-ray crystallography (Fig. 3). As
with structures of N8:4 and N8:5, the structure of N8:6 bears much
similarity with N8:1, however the pentyloxy pendant group of 6
appears to have re-oriented out of the hydrophobic pocket
(Fig. 3a). The three nitrogens within the triazole group of N8:6
overlay with the position of the guanidino group of N8:5 (Fig. 4),
allowing closure of the 150-loop. In contrast, in N8:7 and N8:8 the
presence of branched alcohol groups beyond the triazole ring causes
reorientation of the ring structure and prevents closure of the 150-
loop (Fig. 3b and c). Examination of the residues within the 150-
cavities of N8:7 and N8:8 reveals that the rearrangement of several
side chains is required to accommodate the triazole-hydroxyl
moieties (Fig. 5a) and allow the formation of further hydrogen
bonding interactions (Fig. 5b). For each complex similar structures
were obtained at a variety of soaking times (data not shown).
Discussion
In our previous studies we demonstrated the synthesis and in vitro
properties of a new class of inhibitors of influenza A NA. While
similar to the established NA inhibitor Oseltamivir carboxylate (1),
these inhibitors contained significant alterations such as the change
in position of the double bond within the carbocycle and incorpora-
tion of a guanidino or substituted-triazole functions at the C-4 posi-
tion (Oseltamivir numbering), leading to increased specificity for
group-1 NA in particular for the triazole-substituted inhibitors13.
Previously some of these inhibitors have been shown to inhibit
growth of laboratory N1 andN2 strains of influenza A atmicromolar
concentrations18. Biological characterization of the parental com-
pounds of this class (4 and 5) presented here indicate that both
inhibit growth of an H1N1 isolate (A/Brisbane59/2007) and
compared favourably to the same assays performed using 1, with
either similar (in the case of 4) or approximately 3-fold lower (in
the case of 5) ED50 values. However, in contrast to 1 and 4, inhibitor 5
showed activity against an Oseltamivir-resistant virus with the
H274Y mutation. While the inhibition of 4 against the H274Y virus
was poor (ED50 . 500 mM), the concentration of 5 required was
approximately 10-fold higher than for wild-type virus (ED50 5
34 mM compared to ED50 5 3.9 mM). While the ED50 value of 5
was increased by the incorporation of the H274Y mutation, alterna-
tive compounds such as 3 were affected to a greater (100-fold)
extent21. Therefore 5 represents a real and substantial improvement
on the resistance profile of similar compounds.
The structures of the N8:4 and N8:5 complexes are remarkably
similar to N8:1, suggesting that the reduced susceptibility of these
compounds is not due to substantial changes to the position of the
compounds within the active site. Compounds within this class con-
tain a cyclohexene ring with a C2–C3 carbon-carbon double bond, in
contrast to the C2–C7 position present in 1. Although the change in
position of the double bond does not appear to influence the final
position of the pentyloxy side chain in N8:4 or N8:5, the position of
this group within N8:6 indicates that repositioning of the double
bond between C2–C3 in the carbocycle may increase the flexibility
in this region, in agreement with the results of our previous molecu-
lar dynamics simulations15. The complex of 1 and an N1 bearing the
H274Y mutation shows that E276 is forced into the hydrophobic
Table 1 | Comparison of ED50 (mM) to wild-type and Oseltamivir-
resistant (H274Y) strains
Influenza strain\Compounds 1 4 5
A/Brisbane/59/2007 (WT) 12 12 3.9
A/Brisbane/59/2007-like (H274Y) .500 .500 34
Figure 2 | Comparison of the binding of 4 and 5 to N8 with structures of
existing NA inhibitors. Superposition of N8:4 (dark green, (a)) or N8:5
(cyan, (b–d)) with apo-N8 (2HT5, white, all panels), N8:Oseltamivir(1)
(2HT8, gold, (a) and (b)), N8:Zanamivir(2) (2HTQ, dark blue, (c)) and
N8:Peramivir(3)(2HTU, purple, (d)). Inhibitor binding leads to
repositioning of active site residues E119, D151, and E276 (shown as sticks)
and closure of the 150-loop (indicated by an arrow).
www.nature.com/scientificreports
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pocket and the pentyloxy group shifts 2 A˚ out of the enzyme active
site22. Rather than a change in the rotameric conformation of this
pendant group, this is achieved by slight twisting of the entire ligand
within the active site, removing other groups from their optimal
positions. It is possible that the differences in the position of the
double bond between 1 and 5 allow the pentyloxy group to move
without the same distortions, reducing the impact of themutation on
ligand binding. Indeed, while most of the atoms within the cyclohex-
ene ring of N8:5 overlay closely with their counterparts in N8:1, the
position of C7 is more similar to that observed in the structure of 1
bound to an N1 bearing the H274Y mutation (Supplementary
Fig. S1).
The increased activity of 5 against bothwild-type andOseltamivir-
resistant influenza in comparison to 4 is likely to be due to the
additional contacts made by the guanidino group present within 5
(Fig. 6). The position of this group within the NA active site is very
similar to its position in the structure of the N8:2 complex (but
distinct from the same group in N8:3). As with N8:2, the guanidino
group of N8:5 forms additional hydrogen bonding contacts with the
carboxyls of E119 and E227 and the backbone carbonyls of W178
and D151. Comparison with N8:4 indicates that these direct hydro-
gen bonds replace a looser network of water-mediated interactions,
with retention of only the direct contact between the amino group of
4 and E119. Perhaps surprisingly, these additional contacts only
result in 3-fold decreases in Ki13 and ED50, in comparison to the
100–200-fold decreases observed between 2 and its amino derivative,
4-amino-DANA23. This may indicate that the increased enthalpic
benefit of the additional hydrogen bonding interactions may come
at an entropic cost not observed in their more hydrophilic DANA-
based counterparts. As outlined above, the scaffold employed in
these compounds may allow greater flexibility of the pentyloxy side
chain. Furthermore, unlike the weaker interactions surrounding
the amino group of 4, the arrangement of the hydrogen-bonding
network seems to anchor 5 by the guanidino and carboxylic acid
groups, allowing the ligand to pivot from this position. Therefore
the combination of this scaffold and the added interactions formed
by the guanidino moiety may be to compensate for the H274Y
resistance mutation at the cost of decreased potency against wild-
type NA. Interestingly, the guanidine derivative of 1 showed little or
no improvement compared to 1 in functional assays usingNA (either
wild-type or H274Y)24. This would imply that it is not just guanidino
function, but the combination of both the new scaffold (change in
position of the double bond) and the guanidino group, contributing
towards the observed undiminished activity of compound 5 against
the H274Y mutation. Overall, the ligand may be capable of binding
more tightly, and in more positions, than 1.
Recent studies have highlighted the 150-cavity of group-1 NAs as
a potential source for increased specificity in NA antagonists.
Previously, several compounds have been developed to occupy this
cavity using bulky hydrophobic groups to lock the 150-loop in an
open conformation11,12. Seeking to similarly exploit this cavity by an
alternative approach, we have developed a series of inhibitors incorp-
orating a triazole group at the C4 position of 4. Interestingly, com-
plexes of three representatives of this class displayed two distinct
binding modes (Figs. 3 and 4). Unexpectedly, the structure of the
N8:6 complex indicated that the 150-loop was able to close around
the triazole group, sandwiching it between D151 and E119. In this
position, the nitrogen atoms of the triazole group occupy similar
positions to the guanidino group of 5, retaining contact with the
carbonyl of W178. In contrast, the triazole groups of N8:7 and
N8:8 are rotated by approximately 135u, resulting in the branched
alcohol groups extending into the 150-cavity. Consequentially, in
order to accommodate these groups, the positions of several residues
within the pocket are relocated. In particular, to avoid a steric clash
with the isopropanol group of 7, the guanidino group of R156 has
rotated 120u away from the ligand (Fig. 5a). To enable thismovement
the side chain of Q136 has moved approximately 2 A˚ away from
the ligand, relative to its position in N8:5. Similar movements
are observed in N8:8 to accommodate the tert-propanol group.
Additionally, in both N8:7 and N8:8, D151 has relocated slightly
further out of the active site to allow engagement with the 3-nitrogen
of the triazole group. Whilst the electron density surrounding the
alkyl-alcohol groups within these structures only allows for tentative
placement of the hydroxylmoieties, in bothN8:7 andN8:8 this group
is likely to form at least one hydrogen bond with the enzyme active
site (Fig. 5b, Supplementary Fig. S2).
In summary, 5 has a reduced resistance susceptibility for the
H274Y mutation in comparison to the established NA antagonist
Oseltamivir. This is achieved by a combination of the repositioning
of the double-bond within the carbocyle, giving greater flexibility,
and additional contacts formed by the guanidinium function.
Furthermore, 5 is bound very tightly by two anchor points: the H-
bonding networks at the guanidinium function and the interactions
of arginine triads with the carboxylate function. There is a pivoting of
the ring about these anchor points. We propose that this compound
is held so tightly that it is able to overcome the H274Y mutation just
by maintaining an alternative pose.
Regarding the triazole-extended derivatives 6–8, the 150 cavity is
certainly occupied but one sacrifices binding activity because the
Figure 3 | Two distinct binding modes of triazole-containing influenza inhibitors 6-8. Surface representations of the enzyme active site in N8:6 (a),
N8:7 (b) and N8:8 (c) complexes, with ligand in stick format. The 150-cavity (indicated by an asterisk (*)) of N8:7 and N8:8 complexes remains open, in
contrast to the complex with 6, where the 150-loop is closed.
Figure 4 | Orientation of the 1,2,3-triazole groups of 6 and 7.
Superimposition of (a) 5 (cyan) and 6 (green) and (b) 5 and 7 (pale blue) as
bound within the N8:5, N8:6, and N8:7 complexes, respectively. The
triazole nitrogen atoms (indicated by an arrow) of 6 overlay with the
guanidino moiety of 5, whereas in N8:7 this group is rotated approximately
135u, leading to a repositioning of the alkyl-alcohol functional group.
www.nature.com/scientificreports
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hydrogen-bonding network seen with the guanidinium or amino
function in 4 or 5 has been compromised. The results are corrobo-
rated by the MD studies in which this group is not stable in the 150
cavity but exits the subsite periodically15.
Methods
Viruses. An influenza A virus type strain A/Brisbane/59/2007 (H1N1) was provided
by the WHO National Influenza Centre, National Microbiology Laboratory (NML),
Winnipeg, Canada. A/Brisbane/59/2007-like oseltamivir-resistant strain was isolated
and provided by the Provincial Health Services Authority (PHSA)-British Columbia
Centre for Disease Control (BCCDC) Virology Laboratory, Vancouver, Canada. The
Oseltamivir-resistant isolate was identified as A/Brisbane/59/2007-like by
hemagglutination inhibition assays using strain-specific antisera and by genome
sequencing. The Oseltamivir resistance was determined by an enzyme inhibition
assay by NML. The H274Y mutation was confirmed by sequencing as well as by the
BCCDC H274Y SNP assay.
Virus inhibition assay. The inhibitory effect was tested in MDCK cells as previously
described18. Monolayers were infected with 50 TCID50 of either WT or H274Y virus
in the presence of various concentrations of compounds in quadruplicates in 96 well
plates. After 4 days incubation the effect was quantitatively evaluated by a neutral red
(NR) dye uptake assay25,26. Briefly, the monolayers were stained with 0.01% NR for 2
hours in DMEM and washed twice with phosphate buffered saline. After air-drying,
the incorporated NR was extracted with 100 ml of guanidine-HCl (3 M in water) and
the concentration of releasedNRwasmeasured by amicroplate reader atOD490. ED50
was calculated based on the measurement of uninfected control monolayers as 100%
protection (OD490 5 0.847) and no test compound control (with 50TCID50 A/
Brisbane) as 0% protection (OD490 5 0.086 and 0.082 for WT and H274Y,
respectively).
ProteinX-ray crystallography.N8 sialidase fromA/Duck/Ukraine/1/63 (H3N8)was
prepared from virus grown in hen’s eggs. Sialidase was released from purified virions
by bromelain digestion, and purified as described previously4. Crystals of N8 protein
were grown by vapour diffusion in hanging drops consisting of 1 ml concentrated
protein solution (8 mgml21 in 50 mM Tris-HCl pH8.0) and 1 ml reservoir solution
(40% (6)-2-methyl-2,4,-pentanediol (MPD)). Crystals of N8 sialidase were soaked
reservoir solution containing 1 mM compound for 5 min (4 and 7), 60 min (6 and 8)
or 16 hours (5), although similar results were also obtained at alternative soaking
times. Data were collected on an in-house rotating anode (RA Micro7 HFM) and a
Saturn944 CCD at 100 K and processed withHKL200027. Refinement was carried out
using PHENIX28, combined with manual model building with Coot29. Statistical
support for the structures obtained is presented in Supplementary Table S1.
Structural data have been deposited with the Protein Data Bank with accession codes
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